1378. Evaluation of the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae, including isolates resistant to ceftazidime-avibactam
Session: Poster Abstract Session: Novel Agents
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • IDWeek 2018_Mero-vabor poster_FINAL.pdf (385.3 kB)
  • Background:

    Meropenem-vaborbactam (M-V) is a novel antibiotic for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections. Our objective was to determine the in vitro activity of meropenem-vaborbactam against genetically-diverse CRE isolates, including those that have developed resistance to ceftazidime-avibactam (C-A).

    Methods:

    Minimum inhibitory concentrations (MICs) were determined for meropenem (MER), M-V, and C-A by reference broth microdilution (BMD) methods in triplicate. Vaborbactam and avibactam were tested at fixed concentrations of 8 and 4 µg/ml, respectively. Quality control strains were used and within expected ranges. Polymerase chain reaction (PCR) with DNA sequencing were used to detect resistance determinants, including Klebsiella pneumoniae carbapenemase (KPC) subtypes and porin mutations.

    Results:

    117 CRE isolates were tested, including K. pneumoniae (Kp; n=83), E. cloacae (n=17), E. coli (n=10), and E. aerogenes (n=7). Seventy-nine percent harbored blaKPC. KPC subtypes included KPC-2 (n=32), KPC-3 (n=41), KPC-3 variants (n=16), and KPC [not typed] (n=4, all E. coli). Among 74 K. pneumoniae, 95% had a premature stop codon in ompk35 and ompK36 genotypes included wild-type (n=48), IS5 insertion (n=13), 135-136 DG duplication (n=9), and other mutations (n=4). The median (range) MICs for MER, C-A, and M-V were 8 (0.06 - ≥128), 1 (0.25 - ≥512), and 0.03 (0.015 – 16), respectively. Corresponding rates of susceptibility were 23%, 84%, and 98%, respectively. 53% and 95% of C-A resistant isolates were susceptible to MER and M-V, respectively. Among Kp, C-A MICs did not vary by KPC subtype or porin genotype. On the other hand, median M-V MICs were higher among KPC-2 than KPC-3 Kp (0.12 vs 0.03; P=0.002), and among Kp with ompK36 porin mutations compared to wild-type (0.25 vs 0.03; P<0.001). Among Kp with KPC-3 variants (n=16), the median M-V MIC was 0.03 (0.015 – 2); 100% were M-V susceptible. Median M-V MICs did not vary by CRE species. Only 2 isolates were M-V resistant, both were E. cloacae that did not harbor blaKPC.

    Conclusion:

    M-V demonstrates high rates of in vitro susceptibility against diverse CRE isolates, including those that are resistant to C-A. As this agent is introduced into the clinic, it will be important to identify K. pneumoniae isolates harboring KPC-2 with ompK36 porin mutations that demonstrate higher MICs.

    William R. Wilson, PharmD1,2, Ellen Kline, MS3, Chelsea Jones, BA3, Kristin Morder, BA4, Cornelius J. Clancy, M.D.5, M. Hong Nguyen, MD6 and Ryan K. Shields, PharmD7, (1)Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA, (3)University of Pittsburgh, Pittsburgh, PA, (4)University of Pittsbugh, Pittsburgh, PA, (5)Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, (6)Infectious Disease, University of Pittsburgh, Pittsburgh, PA, (7)University of Pittsburgh, School of Medicine, Pittsburgh, PA

    Disclosures:

    W. R. Wilson, None

    E. Kline, None

    C. Jones, None

    K. Morder, None

    C. J. Clancy, None

    M. H. Nguyen, Merck: Grant Investigator , Research grant . Astellas: Grant Investigator , Research grant .

    R. K. Shields, None

    See more of: Novel Agents
    See more of: Poster Abstract Session
    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.